ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ORI Finds Misconduct By Two Researchers

December 8, 1995

American Cancer Society Awards its Medal of Honor

May 24, 2013

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

In Brief: Pretreatment Critical In Antimetic Therapy, Sallan Says; Aging/Cancer Symposium Planned

July 11, 1980

Organ Systems Program Reorganization Complete; Annual Conferences To Replace Working Groups

May 26, 1989

CMS Draft Coverage Decision Nixes Virtual Colonoscopy

February 13, 2009